MX385854B - Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. - Google Patents
Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.Info
- Publication number
- MX385854B MX385854B MX2016002177A MX2016002177A MX385854B MX 385854 B MX385854 B MX 385854B MX 2016002177 A MX2016002177 A MX 2016002177A MX 2016002177 A MX2016002177 A MX 2016002177A MX 385854 B MX385854 B MX 385854B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- rheumatoid arthritis
- neutralizing antibodies
- analgesics
- csf neutralizing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871904P | 2013-08-30 | 2013-08-30 | |
| US201361871900P | 2013-08-30 | 2013-08-30 | |
| PCT/EP2014/068489 WO2015028657A1 (en) | 2013-08-30 | 2014-09-01 | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016002177A MX2016002177A (es) | 2016-06-28 |
| MX385854B true MX385854B (es) | 2025-03-18 |
Family
ID=51454704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002177A MX385854B (es) | 2013-08-30 | 2014-09-01 | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. |
| MX2021010472A MX2021010472A (es) | 2013-08-30 | 2016-02-18 | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010472A MX2021010472A (es) | 2013-08-30 | 2016-02-18 | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10745475B2 (enExample) |
| EP (2) | EP3889178A1 (enExample) |
| JP (4) | JP2016536327A (enExample) |
| KR (3) | KR20240090993A (enExample) |
| CN (2) | CN118178647A (enExample) |
| AU (3) | AU2014314053C1 (enExample) |
| BR (1) | BR112016003293A8 (enExample) |
| CA (1) | CA2922251C (enExample) |
| ES (1) | ES2860480T3 (enExample) |
| MX (2) | MX385854B (enExample) |
| RU (1) | RU2714919C2 (enExample) |
| WO (1) | WO2015028657A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050734A1 (en) | 2003-05-15 | 2004-12-02 | Ampio Pharmaceuticals, Inc. | Treatment of t-cell mediated diseases |
| EP2766029B1 (en) | 2011-10-10 | 2020-03-25 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
| AU2015305611B2 (en) | 2014-08-18 | 2020-04-23 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| PL3328887T3 (pl) * | 2016-09-19 | 2021-12-27 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Przeciwciała anty-gm-csf i ich zastosowania |
| TWI716668B (zh) | 2017-02-01 | 2021-01-21 | 耶魯大學 | 心臟衰竭及心腎症候群之精準治療 |
| MX2020006882A (es) | 2018-01-05 | 2020-09-07 | Novo Nordisk As | Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion. |
| SG11202008934PA (en) * | 2018-03-14 | 2020-10-29 | Univ Indiana Res & Tech Corp | Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS59147297A (ja) | 1983-02-10 | 1984-08-23 | 株式会社日立製作所 | 原子炉圧力容器の耐震構造 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| AU2001232267A1 (en) | 2000-02-14 | 2001-08-20 | Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases | Remedies for hepatitis c |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2002324556A1 (en) | 2001-07-25 | 2003-02-17 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| ES2392073T3 (es) | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| EP1576011B1 (en) | 2002-10-30 | 2009-08-12 | Genentech, Inc. | Inhibition of il-17 production |
| EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
| EP1593690B1 (en) | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2005316405A1 (en) | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| ME02191B (me) | 2005-04-18 | 2016-02-20 | Amgen Res Munich Gmbh | Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga |
| NZ564027A (en) | 2005-05-18 | 2011-06-30 | Morphosys Ag | Anti-GM-CSF antibodies and uses therefor |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| RS55526B1 (sr) | 2006-02-08 | 2017-05-31 | Morphotek Inc | Antigenski gm-csf peptidi i antitela gm-csf |
| ES2395839T3 (es) | 2006-03-27 | 2013-02-15 | Medimmune Limited | Miembro de unión para el receptor GM-CSF |
| CN101605547A (zh) * | 2006-11-21 | 2009-12-16 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| US7951368B2 (en) | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| MX2010005291A (es) | 2007-11-13 | 2010-11-12 | Evec Inc | Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos. |
| CN102037016B (zh) | 2008-04-28 | 2015-06-03 | 卡罗拜奥斯制药公司 | 针对粒细胞巨噬细胞集落刺激因子的抗体 |
| AU2009242088B2 (en) | 2008-04-29 | 2014-08-21 | Amgen Research (Munich) Gmbh | Inhibitors of GM-CSF and IL-17 for therapy |
| ES2978209T3 (es) | 2008-12-22 | 2024-09-09 | Univ Melbourne | Tratamiento del dolor |
| EP2427495A1 (en) | 2009-05-05 | 2012-03-14 | MorphoSys AG | Treatment for multiple sclerosis |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| CN102686241A (zh) | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| JP6239517B2 (ja) | 2011-10-10 | 2017-11-29 | メディミューン リミテッド | 関節リウマチの治療法 |
| EP3916013A1 (en) | 2012-09-20 | 2021-12-01 | MorphoSys AG | Treatment for rheumatoid arthritis with anti-gm-csf antibody |
| JP6339578B2 (ja) | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| CN109562493B (zh) | 2016-08-03 | 2021-10-26 | 古河电气工业株式会社 | 含金属粒子的组合物 |
-
2014
- 2014-09-01 RU RU2016109944A patent/RU2714919C2/ru active
- 2014-09-01 KR KR1020247017478A patent/KR20240090993A/ko active Pending
- 2014-09-01 KR KR1020167007575A patent/KR20160044035A/ko not_active Ceased
- 2014-09-01 MX MX2016002177A patent/MX385854B/es unknown
- 2014-09-01 ES ES14758384T patent/ES2860480T3/es active Active
- 2014-09-01 KR KR1020227010431A patent/KR20220045064A/ko not_active Ceased
- 2014-09-01 CA CA2922251A patent/CA2922251C/en active Active
- 2014-09-01 EP EP21161450.8A patent/EP3889178A1/en active Pending
- 2014-09-01 US US14/913,578 patent/US10745475B2/en active Active
- 2014-09-01 BR BR112016003293A patent/BR112016003293A8/pt not_active Application Discontinuation
- 2014-09-01 AU AU2014314053A patent/AU2014314053C1/en not_active Ceased
- 2014-09-01 EP EP14758384.3A patent/EP3039039B1/en active Active
- 2014-09-01 CN CN202410511905.9A patent/CN118178647A/zh active Pending
- 2014-09-01 WO PCT/EP2014/068489 patent/WO2015028657A1/en not_active Ceased
- 2014-09-01 JP JP2016537322A patent/JP2016536327A/ja active Pending
- 2014-09-01 CN CN201480047403.XA patent/CN105705518A/zh active Pending
-
2016
- 2016-02-18 MX MX2021010472A patent/MX2021010472A/es unknown
-
2020
- 2020-03-11 JP JP2020042267A patent/JP2020109108A/ja active Pending
- 2020-06-12 AU AU2020203917A patent/AU2020203917A1/en not_active Abandoned
- 2020-08-17 US US16/995,617 patent/US11795216B2/en active Active
-
2022
- 2022-05-02 JP JP2022076303A patent/JP2022105160A/ja active Pending
-
2023
- 2023-08-04 AU AU2023210647A patent/AU2023210647A1/en not_active Abandoned
-
2024
- 2024-06-27 JP JP2024103720A patent/JP2024123249A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010472A (es) | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. | |
| CL2016001435A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncologia, neurología e inmunología | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| MX377190B (es) | Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. | |
| PH12016500141A1 (en) | Methods of treating sporadic inclusion body myositis | |
| MX2015011897A (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| MX2019013123A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| EA201591137A1 (ru) | Ингибиторы mk2 и их применения | |
| UA117466C2 (uk) | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| CL2015002655A1 (es) | Moduladores de p2x7 | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| UA117011C2 (uk) | Фармацевтичний склад омекамтиву мекарбілу і спосіб його застосування | |
| NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| GB201322049D0 (en) | Incremental and collocated redistribution for expansion of an online shared nothing database | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| CU24407B1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| IN2013MU03641A (enExample) |